Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine

Journal of Clinical Microbiology

Volumn 37, Issue 10, 1999, Pages 3338-3347

  Allen, Marchelle I ^a   Gauthier, Josee ^a   DesLauriers, Manon ^b   Bourne, Eric J ^a   Carrick, Kevin M ^a   Baldanti, Fausto ^c   Ross, Lisa L ^a   Lutz, Michael W ^a   Condreay, Lynn D ^a  

^a GLAXOSMITHKLINE   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; LAMIVUDINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; HEPATITIS B; HUMAN; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROLOGY;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0032849751     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.10.3338-3347.1999     Document Type: Article

References (32)

1. Allen, M. I., M. DesLauriers, C. W. Andrews, G. A. Tipples, K.-A. Walters, D. L. J. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Atkins, M., C. M. Hunt, N. Brown, F. Gray, L. Sanathanan, M. Woessner, C. L. Lai, G. Dusheiko, J. Dienstag, T. Wright, J. Barnard, E. Bourne, and L. Condreay. 1998. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients, abstr. 625. Hepatology 28:319.
3. Bartholomeusz, A., and S. A. Locarnini. 1997. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int. Antiviral News 5:123-124.
4. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzendahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis B virus resistant to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
5. Bassler, H. A., S. J. A. Flood, K. J. Livak, J. Marmaro, R. Knorr, and C. A. Batt. 1995. Use of a fluorogenic probe in a PCR-based assay for the detection of Listeria monocytogenes. Appl. Environ. Microbiol. 61:3724-3728.
6. Bowden, S. 1997. Hepatitis B: treatment for the 21st century. Antivir. Chem. Chemother. 8:77-82.
7. Chayama, K., Y. Suzuki, M. Kobayashi, M. Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, N. Murashima, K. Ikeda, and H. Kumada. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology 27:1711-1716.
8. Chen, X., B. Zehnbauer, A. Gnirke, and P.-Y. Kwok. 1997 Fluorescence energy transfer detection as a homogeneous DNA diagnostic method. Proc. Natl. Acad. Sci. USA 94:10756-10761.
9. Davey, S. 1996. State of the world's vaccines and immunization.
10. Doong, S.-L., C-H. Tsai, R. F. Schinazi, D. C. Liotta, and Y.-C. Cheng. 1991. Inhibition of the replication of hepatitis B virus In Vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
11. Fallows, D. A., and S. P. Goff. 1995. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J. Virol. 69:3067-3073.
12. Gauthier, J., E. J. Bourne, M. W. Lutz, L. M. Crowther, J. L. Dienstag, N. A. Brown, and L. D. Condreay. Quantitative assessment of HBV viremia and emergence of YMDD variants in chronic hepatitis B patients treated with lamivudine. J. Infect. Dis., in press.
13. Honkoop, P., H. G. M. Niesters, R. A. M. de Man, A. D. M. E. Osterhaus, and S. W. Schalm. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. J. Hepatol. 26:1393-1395.
14. Ibrahim, M. S., J. J. Esposito, P. B. Jahrling, and R. S. Lofts. 1997. The potential of 5′ nuclease PCR for detecting a single-base polymorphism in Orthopoxvirus. Mol. Cell. Probes 11:143-147.
15. Jansen, R. W., L. C. Johnson, and D. R. Averett. 1993. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific PCR assay. Antimicrob. Agents Chemother. 37:441-447.
16. Kapke, G. F., G. Watson, S. Sheffler, D. Hunt, and C. Frederick. 1997. Comparison of the chiron quantiplex branched DNA (bDNA) assay and the Abbott genostics solution hybridization assay for quantification of hepatitis B viral DNA. J. Viral Hepatitis 4:67-75.
17. Kramvis, A., S. Bukofzer, and M. C. Kew. 1996. Comparison of hepatitis B virus DNA extractions from serum by the QIAamp blood kit, GeneReleaser, and the phenol-chloroform method. J. Clin. Microbiol. 34:2731-2733.
18. Ladner, S. K., T. J. Miller, and R. W. King. 1998. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42:2128-2131.
19. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998 A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group (see comments). N. Engl. J. Med. 339:61-68.
20. Lee, L. G., C. R. Connell, and W. Bloch. 1993. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res. 21:3761-3766.
21. Ling, R., D. Mutimer, M. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
22. Livak, K. J., S. J. A. Flood, J. Marmaro, W. Giusti, and K. Deetz. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4:357-362.
23. Mast, E., and M. Alter. 1993. Epidemiology of viral hepatitis: an overview. Semin. Virol. 4:273-283.
24. McGoldrick, A., J. P. Lowings, G. Ibata, J. J. Sands, S. Belak, and D. J. Paton. 1998. A novel approach to the detection of classical swine fever virus by RT-PCR with a fluorogenic probe (Taqman). J. Virol. Methods 71:125-135.
25. Nakahori, S., O. Yokosuka, T. Ehata, W. L. Chuang, F. Imazeki, Y. Ito, and M. Ohto. 1995. Detection of hepatitis B virus precore stop codon mutants by selective amplification method: frequent detection of precore mutants in hepatitis B e antigen positive healthy carriers. J. Gastroenterol. Hepatol. 10:419-425.
26. Niesters, H. G., P. Honkoop, E. B. Haagsma, R. A. de Man, S. W. Schalm, and A. D. Osterhaus. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177:1382-1385.
27. Ratnamohan, V. M., A. L. Cunningham, and W. D. Rawlinson. 1998. Removal of inhibitors of CSF-PCR to improve diagnosis of herpesviral encephalitis. J. Virol. Methods 72:59-65.
28. Schalm, S. W., R. A. de Man, R. A. Heijtink, and H. G. M. Niesters. 1995. New nucleoside analogues for chronic hepatitis B. J. Hepatol. 22:52-56.
29. Sherlock, S., and J. Dooley. 1997. Diseases of the liver and biliary system, 10th ed. Blackwell Science, Oxford, England.
30. Swan, D. C., R. A. Tucker, B. P. Holloway, and J. P. Icenogle. 1997. A sensitive, type-specific, fluorogenic probe assay for detection of human papillomavirus DNA. J. Clin. Microbiol. 35:886-891.
31. Tassopoulos, N. C., R. Volpes, G. Pastore, J. Heathcote, M. Buti, R. D. Goldin, S. Hawley, J. Barber, L. Condreay, D. F. Gray, and the Lamivudine Pre-core Mutant Study Group. 1999. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
32. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and D. L. J. Tyrrell. 1996. Mutations in HBV RNA-Dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.